Room For More? Karyopharm Targets Highly Refractory Myeloma Patients
Executive Summary
Crowded field of multiple myeloma has yet another contender – Karyopharm's first-in-class SIN/XPO1 antagonist selinexor – but company thinks "penta-refractory" approach will be a good calling card.
You may also be interested in...
Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers
Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.